Financing ·
Pulse Biosciences, Inc. entered into an equity distribution agreement with Mizuho Securities USA LLC on August 6…
PLSEPulse Biosciences, Inc.
Pulse Biosciences, Inc. entered into an equity distribution agreement with Mizuho Securities USA LLC on August 6, 2026, establishing a sales facility to offer and sell shares of its common stock from time to time. The company may issue up to $75,000,000 in aggregate offering price under this arrangement, though it is not obligated to sell any specific amount. Mizuho will act as sales agent using commercially reasonable efforts to sell shares via at-the-market offerings or other permitted methods, charging a commission of up to 3.0% of the gross sales price. The company may suspend solicitations and offers at any time. This equity issuance capability is facilitated through an effective Form S-3 registration statement filed in February 2026. Pulse Biosciences, Inc. operates in the medical device industry, developing electroporation technologies for cancer treatment.